Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/20865| Title: | Status of PCSK9 Monoclonal Antibodies in Australia. | Austin Authors: | Scherer, Daniel J;Nelson, Adam J;O'Brien, Richard C ;Kostner, Karam M;Hare, David L ;Colquhoun, David M;Barter, Philip J;Aylward, Philip;Nicholls, Stephen J;Watts, Gerald F | Affiliation: | Department of Medicine, Monash University, Melbourne, Vic, Australia School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia Flinders University and Medical Centre, Adelaide, SA, Australia Department of Cardiology, Mater Hospital, University of Queensland, Brisbane, Qld, Australia School of Medicine, Faculty of Medicine and Health Sciences, University of Western Australia, Perth, Australia Lipid Disorders Clinic, Department of Cardiology, Royal Perth Hospital, Perth, Australia School of Medicine, University of Queensland, Brisbane, Qld, Australia Wesley Medical Centre, Wesley Hospital and Greenslopes Private Hospital, Brisbane, Qld, Australia Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Vic, Australia Cardiology University of Melbourne Clinical School Endocrinology South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia University of Adelaide, Adelaide, SA, Australia |
Issue Date: | Oct-2019 | Date: | 2019-05-08 | Publication information: | Heart, Lung & Circulation 2019; 28(10): 1571-1579 | Abstract: | Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAb) have progressed from showing marked low density lipoprotein cholesterol lowering in early phase trials through to reducing cardiovascular events in large clinical outcome trials. Recently in Australia, the indication for evolocumab has been expanded to include both heterozygous and homozygous familial hypercholesterolaemia under the Pharmaceutical Benefits Scheme (PBS). With prices remaining high currently their use in non-familial hypercholesterolaemia in Australia remains by private prescription only at this stage. This manuscript summarises the major outcomes trials of the PCSK9 mAbs and the secondary analyses that have assessed their benefits in high risk patient groups, and describes the consensus of authors on which patients would most likely benefit from PCSK9 mAb therapy. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/20865 | DOI: | 10.1016/j.hlc.2019.04.014 | ORCID: | Journal: | Heart, Lung & Circulation | PubMed URL: | 31104887 | Type: | Journal Article | Subjects: | Atherosclerosis Cardiovascular risk Lipids PCSK9 inhibitors |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.